Loading organizations...
§ Private Profile · Shanghai, China
Lanova Medicine is a technology company.
Lanova Medicine is a clinical-stage biotechnology company developing innovative biologic cancer therapies. It employs proprietary platforms, including LM-Abs™, LM-ADC™, and LM-TCE™, to engineer antibody-drug conjugates and multi-specific antibodies. This technical approach applies deep insights into the tumor microenvironment, addressing solid tumors and hematological malignancies.
Founded in September 2019 in Shanghai, LaNova Medicine was established by Dr. Crystal Qin, President and CEO. A Medical Doctor and Ph.D., Dr. Qin believed sophisticated antibody engineering and understanding the tumor microenvironment were key to effective cancer therapies. This conviction drives innovative drug discovery.
LaNova Medicine's products target patients with life-threatening cancers, including advanced solid tumors and hematological malignancies. Its vision redefines the therapeutic landscape by advancing programs through clinical development, aiming to improve outcomes and quality of life for cancer patients.
Lanova Medicine has raised $133.0M across 3 funding rounds.
Lanova Medicine has raised $133.0M in total across 3 funding rounds.
Lanova Medicine has raised $133.0M across 3 funding rounds. Most recently, it raised $42.0M LaNova Medicines - Series C in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2024 | $42M Series C | — | Qiming Venture Partners | Announced |
| Mar 1, 2021 | $5M Seed | — | MSA Capital | Announced |
| Dec 1, 2020 | $86M Series A | — | Qiming Venture Partners | Announced |
Lanova Medicine has raised $133.0M in total across 3 funding rounds.
Lanova Medicine's investors include Qiming Venture Partners, MSA Capital.
LaNova Medicines is a clinical-stage biotechnology company founded in 2019 and headquartered in Shanghai, focused on discovering and developing innovative antibody-based cancer therapies. Its mission, "Care for Life, Dedicate to Innovation," drives the company to create first-in-class and best-in-class biologic treatments targeting the tumor microenvironment, particularly in oncology and immuno-oncology. LaNova serves patients with advanced solid tumors and other cancers by addressing significant unmet medical needs through novel therapies such as bispecific antibodies and antibody-drug conjugates (ADCs). The company has demonstrated strong growth momentum, advancing multiple candidates into clinical trials and securing high-profile licensing deals with global pharmaceutical leaders like Merck and AstraZeneca[1][2][3].
LaNova Medicines was founded in September 2019 by a team with deep expertise in antibody discovery and drug development, combining decades of experience from multinational pharmaceutical and local biotech sectors. The idea emerged from a vision to transform global cancer care by leveraging cutting-edge antibody technologies targeting GPCRs and multi-transmembrane proteins. Early traction included rapid establishment of innovative R&D platforms and a differentiated pipeline within just a few years, culminating in significant clinical progress and strategic partnerships with major pharma companies[1][2].
LaNova rides the wave of innovation in China’s biotech sector, which has evolved from a generics-focused industry to a global hub for novel drug discovery. The timing is critical as immuno-oncology and bispecific antibody therapies gain prominence worldwide, driven by unmet needs in cancer treatment and advances in biologics. Market forces such as increasing investment in biotech, regulatory support in China, and global pharma interest in Chinese innovation favor LaNova’s growth. By developing cutting-edge therapies and securing international partnerships, LaNova influences the broader ecosystem by elevating China’s status in global oncology drug development and accelerating access to novel cancer treatments[1][3].
Looking ahead, LaNova Medicines is poised to expand its clinical pipeline and deepen collaborations with global pharmaceutical companies. Trends shaping its journey include the growing adoption of bispecific antibodies and ADCs in oncology, advances in precision medicine, and increasing integration of AI in drug discovery. As LaNova transitions into a wholly owned subsidiary of Sino Biopharmaceutical, it may leverage greater resources to accelerate commercialization and global market entry. Its influence is likely to grow as it continues to deliver innovative therapies that address critical gaps in cancer care, reinforcing its role as a key player in the evolving biotech landscape[3].